Form 4: Alnylam CFO Poulton Reports Equity Transactions

Alnylam Pharmaceuticals' CFO, Jeffrey V. Poulton, reported the acquisition of restricted stock units and stock options, alongside sales of common stock to cover tax obligations.

Summary

• Jeffrey V. Poulton, EVP, Chief Financial Officer of Alnylam Pharmaceuticals, Inc. (ALNY), reported several equity transactions on March 2, 2026.
• Poulton acquired 4,769 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.0, which will vest over a three-year period.
• He also acquired 10,480 stock options with an exercise price of $325.07, which will vest over a four-year period and expire on March 2, 2036.
• Poulton disposed of a total of 2,084 shares of Common Stock through multiple transactions at weighted average prices ranging from $323.62 to $332.64.
• These sales were mandatory 'sell-to-cover' transactions to satisfy minimum statutory tax withholding obligations related to equity awards.
• Following these transactions, Poulton directly beneficially owns 64,273 shares of Common Stock and 10,480 derivative securities (stock options).
• Additionally, Poulton indirectly owns 57 shares of Common Stock through a managed account (401(k) plan).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While there were sales of shares, these were for tax purposes, and the significant grants of new RSUs and stock options demonstrate continued executive alignment and commitment to the company's long-term performance.

Positives

• The grant of 4,769 Restricted Stock Units (RSUs) and 10,480 stock options aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The RSUs and stock options were granted at a $0.0 acquisition price for RSUs and an exercise price of $325.07 for options, indicating a component of executive compensation.

Negatives

• The disposition of 2,084 shares of Common Stock, although for tax withholding purposes, reduces the direct beneficial ownership of the Chief Financial Officer.

Industry Context

StockSavvy.ai notes that these transactions are typical for executive compensation packages in the biotechnology and pharmaceutical industries, involving the grant of equity awards and subsequent 'sell-to-cover' sales for tax obligations. Such filings provide transparency into insider holdings and compensation structures.

Stakeholder Impact

• Shareholders: The grant of equity awards to the CFO aligns management's financial interests with shareholder value creation, potentially fostering long-term growth and stability.
• Employees: The compensation structure, including equity grants, can serve as a benchmark for other executive and key employee incentive programs within the company.

Next Steps

• The Restricted Stock Units (RSUs) will vest over a three-year period, with one-third vesting on each of the first, second, and third anniversaries of the grant date (March 2, 2027, 2028, and 2029).
• The stock options will vest as to 25% of the shares on the first anniversary of the grant date (March 2, 2027) and the remaining shares will vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date (March 2, 2030).

Key Dates

Recommendation

This Form 4 filing details routine executive compensation transactions, including grants of equity awards and sales to cover tax obligations. Such transactions are common and do not typically indicate a change in the company's fundamental outlook or warrant a strong buy or sell recommendation based solely on this information. Investors should consider these transactions as part of a broader analysis of Alnylam Pharmaceuticals' financial performance and strategic direction.

Keywords

ALNY, Alnylam Pharmaceuticals, Jeffrey V. Poulton, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Biotechnology, Pharmaceuticals